---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-387232"
form_type: "8-K"
ticker: "PRLD"
cik: "0001678660"
company_name: "Prelude Therapeutics Inc"
filed_at: "2026-09-10T11:29:55+00:00"
generated_at: "2026-09-10T11:35:27.618306+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Prelude Therapeutics gets FDA clearance to start Phase 1 trial of PRT13722 for HR+ breast cancer

## Summary
- FDA cleared IND for PRT13722, an oral KAT6A selective degrader, for HR+/HER2- breast cancer.
- Phase 1 study expected to begin enrolling patients in Q4 2026.
- Study will evaluate PRT13722 as monotherapy and in combination with endocrine and targeted therapies in adults with locally advanced or metastatic HR-positive, HER2-negative breast cancer.
- Company believes selective KAT6A degradation may improve efficacy and hematological safety vs dual KAT6A/B inhibitors.

## SEC filing metadata
- accession: 0001193125-26-387232
- form_type: 8-K
- ticker: PRLD
- cik: 0001678660
- company_name: Prelude Therapeutics Inc
- filed_at: 2026-09-10T11:29:55+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1678660/000119312526387232/0001193125-26-387232-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1678660/000119312526387232/prld-20260910.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-387232
- JSON: https://secwatch.observer/filing/0001193125-26-387232.json
- Plain text: https://secwatch.observer/filing/0001193125-26-387232.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.